Literature DB >> 28610978

Design, synthesis, and structure-activity relationships of pyrimido[4,5-b]indole-4-amines as microtubule depolymerizing agents that are effective against multidrug resistant cells.

Ravi Kumar Vyas Devambatla1, Wei Li1, Nilesh Zaware1, Shruti Choudhary1, Ernest Hamel2, Susan L Mooberry3, Aleem Gangjee4.   

Abstract

To identify the structural features of 9H-pyrimido[4,5-b]indoles as microtubule depolymerizers, pyrimido[4,5-b]indoles 2-8 with varied substituents at the 2-, 4- and 5-positions were designed and synthesized. Nucleophilic displacement of 2,5-substituted-4-chloro-pyrimido[4,5-b]indoles with appropriate arylamines was the final step employed in the synthesis of target compounds 2-8. Compounds 2 and 6 had two-digit nanomolar potency (IC50) against MDA-MB-435, SK-OV-3 and HeLa cancer cells in vitro. Compounds 2 and 6 also depolymerized microtubules comparable to the lead compound 1. Compounds 2, 3, 6 and 8 were effective in cells expressing P-glycoprotein or the βIII isotype of tubulin, mechanisms that are associated with clinical drug resistance to microtubule targeting drugs. Proton NMR and molecular modeling studies were employed to identify the structural basis for the microtubule depolymerizing activity of pyrimido[4,5-b]indoles.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Conformational restriction; Microtubule depolymerizing agents; Microtubules; Multidrug resistance; Pyrimido[4,5-b]indoles

Mesh:

Substances:

Year:  2017        PMID: 28610978      PMCID: PMC5603926          DOI: 10.1016/j.bmcl.2017.05.085

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  37 in total

1.  Phase II trial of combretastatin A4 phosphate, carboplatin, and paclitaxel in patients with platinum-resistant ovarian cancer.

Authors:  M Zweifel; G C Jayson; N S Reed; R Osborne; B Hassan; J Ledermann; G Shreeves; L Poupard; S-P Lu; J Balkissoon; D J Chaplin; G J S Rustin
Journal:  Ann Oncol       Date:  2011-01-27       Impact factor: 32.976

Review 2.  The tubulin colchicine domain: a molecular modeling perspective.

Authors:  Alberto Massarotti; Antonio Coluccia; Romano Silvestri; Giovanni Sorba; Andrea Brancale
Journal:  ChemMedChem       Date:  2011-10-12       Impact factor: 3.466

3.  Tyrosine kinase inhibitors. 16. 6,5,6-tricyclic benzothieno[3, 2-d]pyrimidines and pyrimido[5,4-b-] and -[4,5-b]ĭndoles as potent inhibitors of the epidermal growth factor receptor tyrosine kinase.

Authors:  H D Showalter; A J Bridges; H Zhou; A D Sercel; A McMichael; D W Fry
Journal:  J Med Chem       Date:  1999-12-30       Impact factor: 7.446

Review 4.  Microtubule inhibitors: Differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistance.

Authors:  Edith A Perez
Journal:  Mol Cancer Ther       Date:  2009-08-11       Impact factor: 6.261

5.  Trastuzumab emtansine for HER2-positive advanced breast cancer.

Authors:  Sunil Verma; David Miles; Luca Gianni; Ian E Krop; Manfred Welslau; José Baselga; Mark Pegram; Do-Youn Oh; Véronique Diéras; Ellie Guardino; Liang Fang; Michael W Lu; Steven Olsen; Kim Blackwell
Journal:  N Engl J Med       Date:  2012-10-01       Impact factor: 91.245

6.  Targeting p53 for Novel Anticancer Therapy.

Authors:  Zhen Wang; Yi Sun
Journal:  Transl Oncol       Date:  2010-02       Impact factor: 4.243

7.  Phase I trial of combretastatin A4 phosphate (CA4P) in combination with bevacizumab in patients with advanced cancer.

Authors:  Paul Nathan; Martin Zweifel; Anwar R Padhani; Dow-Mu Koh; Matthew Ng; David J Collins; Adrian Harris; Craig Carden; Jon Smythe; Nita Fisher; N Jane Taylor; J James Stirling; Shiao-Ping Lu; Martin O Leach; Gordon J S Rustin; Ian Judson
Journal:  Clin Cancer Res       Date:  2012-05-29       Impact factor: 12.531

Review 8.  Multidrug resistance in cancer chemotherapy.

Authors:  N H Patel; M L Rothenberg
Journal:  Invest New Drugs       Date:  1994       Impact factor: 3.850

9.  Synthesis of N(4)-(substituted phenyl)-N(4)-alkyl/desalkyl-9H-pyrimido[4,5-b]indole-2,4-diamines and identification of new microtubule disrupting compounds that are effective against multidrug resistant cells.

Authors:  Aleem Gangjee; Nilesh Zaware; Ravi Kumar Vyas Devambatla; Sudhir Raghavan; Cara D Westbrook; Nicholas F Dybdal-Hargreaves; Ernest Hamel; Susan L Mooberry
Journal:  Bioorg Med Chem       Date:  2012-12-20       Impact factor: 3.641

10.  Phase Ib trial of radiotherapy in combination with combretastatin-A4-phosphate in patients with non-small-cell lung cancer, prostate adenocarcinoma, and squamous cell carcinoma of the head and neck.

Authors:  Q-S Ng; H Mandeville; V Goh; R Alonzi; J Milner; D Carnell; K Meer; A R Padhani; M I Saunders; P J Hoskin
Journal:  Ann Oncol       Date:  2011-07-15       Impact factor: 32.976

View more
  4 in total

1.  Colchicine Binding Site Agent DJ95 Overcomes Drug Resistance and Exhibits Antitumor Efficacy.

Authors:  Kinsie E Arnst; Yuxi Wang; Zi-Ning Lei; Dong-Jin Hwang; Gyanendra Kumar; Dejian Ma; Deanna N Parke; Qiang Chen; Jinliang Yang; Stephen W White; Tiffany N Seagroves; Zhe-Sheng Chen; Duane D Miller; Wei Li
Journal:  Mol Pharmacol       Date:  2019-05-01       Impact factor: 4.436

2.  Potential of substituted quinazolines to interact with multiple targets in the treatment of cancer.

Authors:  Shruti Choudhary; Arpit Doshi; Lerin Luckett-Chastain; Michael Ihnat; Ernest Hamel; Susan L Mooberry; Aleem Gangjee
Journal:  Bioorg Med Chem       Date:  2021-02-12       Impact factor: 3.641

3.  Novel pyrazolo[4,3-d]pyrimidine microtubule targeting agents (MTAs): Synthesis, structure-activity relationship, in vitro and in vivo evaluation as antitumor agents.

Authors:  Farhana Islam; Tasdique M Quadery; Ruoli Bai; Lerin R Luckett-Chastain; Ernest Hamel; Michael A Ihnat; Aleem Gangjee
Journal:  Bioorg Med Chem Lett       Date:  2021-03-09       Impact factor: 2.940

4.  Design, Synthesis, and Biological Evaluation of 5,6,7,8-Tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidines as Microtubule Targeting Agents.

Authors:  Farhana Islam; Arpit Doshi; Andrew J Robles; Tasdique M Quadery; Xin Zhang; Xilin Zhou; Ernest Hamel; Susan L Mooberry; Aleem Gangjee
Journal:  Molecules       Date:  2022-01-05       Impact factor: 4.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.